Daclatasvir for use in treating lung and prostate cancer
AssigneeHenry Ford Health System
InventorsJagadananda Ghosh, Jitender Monga
Life of this patent
Estimating the term…
Abstract
The present invention discloses daclatasvir (DCV) for use in the treatment and/or prevention of cancer, preferably lung cancer and/or prostate cancer, more preferably enzalutamide-resistant prostate cancer.
Claims2
A method of treating cancer in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of daclatasvir (DCV), wherein cancer cells in the subject express higher levels of Tribbles homolog 2 (TRIB2) compared to levels of TRIB2 expressed by counterpart non-cancer cells, wherein:
- (i) the counterpart non-cancer cells are derived from the subject;
- and/or (ii) the counterpart non-cancer cells are derived from a subject not suffering from cancer, and wherein the cancer cells and the counterpart non-cancer cells are derived from prostate tissue;
- wherein, optionally, the cancer cells and the counterpart non-cancer cells are cells of prostate glands.
A method of treating cancer in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of daclatasvir (DCV), wherein cancer cells in the subject express higher levels of Tribbles homolog 2 (TRIB2) compared to levels of TRIB2 expressed by counterpart non-cancer cells, wherein:
- (i) the counterpart non-cancer cells are derived from the subject;
- and/or (ii) the counterpart non-cancer cells are derived from a subject not suffering from cancer, and wherein the cancer cells and the counterpart non-cancer cells are derived from lung tissue;
- wherein, the cancer cells are, or derived from non-small cell lung cancer (NSCLC), small cell lung cancer, adenocarcinomas, squamous cell carcinomas, bronchioalveolar carcinomas, and large cell carcinomas.
Dependencies are inferred from the claim text.